IsoRay – Consensus Indicates Potential 108.7% Upside

Broker Ratings

IsoRay found using ticker (ISR) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 3 and 1.6 calculating the average target price we see 2.17. Now with the previous closing price of 1.04 this would indicate that there is a potential upside of 108.7%. There is a 50 day moving average of 1.2 while the 200 day moving average is 0.96. The market cap for the company is $145m. Company Website:

Isoray, through its subsidiary, IsoRay Medical, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray was founded in 1998 and is headquartered in Richland, Washington.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index